Li Wenbin, Guo Lei, Bi Xingang, Ma Jianhui, Zheng Shan
Department of Pathology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing 100021, China.
Department of Urology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing 100021, China.
Int J Clin Exp Pathol. 2015 Aug 1;8(8):9446-51. eCollection 2015.
Renal epithelioid angiomyolipoma (EAML) is a rare variant of AML (angiomyolipoma) and is often associated with aggressive behaviors. The pathogenesis of EAML has been poorly understood. We analyzed the expression of p53 and Ki-67 by immunohistochemistry (IHC) and investigated p53 mutation analysis in 11 cases of EAML in comparison to classical AML.
P53 and Ki-67 expression status were determined by IHC staining. P53 mutation analysis was performed using bi-directional sequencing.
Renal EAML tumors were significantly associated with more severe to moderate nuclear atypia (100% vs. 36.4%, P = 0.004) and mitotic activity (90.9% vs. 27.3%, P = 0.008) compared with AML tumors. Out of 11 cases of EAML, 8 were positive for p53. There was only 1 case with positive p53 expression in AML cases and expression of p53 protein showed significant difference between EAML and AML tumors (72.7% vs. 9.1%, P = 0.008). In addition, there were 7 AML and 6 EAML cases harbored P72R mutation (SNP) in exon 4 of p53. Compared with AML cases, 2 out of 11 cases of EMAL showed more than 10% positivity for ki-67. The finding of stronger p53 expression in renal EAML might have contributed to their malignant behavior. However, the abnormal p53 expression cannot be entirely explained by p53 mutations in the exons examined.
Thus, the combination of immunohistochemical assessment of tumor antigens might improve our ability to predict the malignant outcome in EAML.
肾上皮样血管平滑肌脂肪瘤(EAML)是血管平滑肌脂肪瘤(AML)的一种罕见变体,常与侵袭性行为相关。EAML的发病机制尚不清楚。我们通过免疫组织化学(IHC)分析了p53和Ki-67的表达,并与经典AML相比,对11例EAML进行了p53突变分析。
通过IHC染色确定p53和Ki-67的表达状态。使用双向测序进行p53突变分析。
与AML肿瘤相比,肾EAML肿瘤与更严重至中度的核异型性(100%对36.4%,P = 0.004)和有丝分裂活性(90.9%对27.3%,P = 0.008)显著相关。在11例EAML中,8例p53呈阳性。AML病例中只有1例p53表达阳性,p53蛋白表达在EAML和AML肿瘤之间存在显著差异(72.7%对9.1%,P = 0.008)。此外,7例AML和6例EAML病例在p53的第4外显子中存在P72R突变(单核苷酸多态性)。与AML病例相比,11例EMAL中有2例Ki-67阳性率超过10%。肾EAML中p53表达更强的发现可能导致了它们的恶性行为。然而,外显子中p53突变不能完全解释p53的异常表达。
因此,肿瘤抗原的免疫组织化学评估相结合可能提高我们预测EAML恶性结局的能力。